As of Jun 02
| -0.0142 / -1.74%|
The 1 analysts offering 12-month price forecasts for Neoleukin Therapeutics Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +86.61% increase from the last price of 0.80.
The current consensus among 2 polled investment analysts is to Hold stock in Neoleukin Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.